<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184089</url>
  </required_header>
  <id_info>
    <org_study_id>ANES.CE.01</org_study_id>
    <nct_id>NCT04184089</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula in Patients Undergoing Ophthalmic Surgeries With Intravenous Sedation</brief_title>
  <official_title>High Flow Nasal Cannula in Patients Undergoing Ophthalmic Surgeries With Intravenous Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High flow nasal cannula provides adequate oxygenation in patients with compromised pulmonary
      function. Very few studies in the literature addressed its use with IV sedation in the OR.
      Successful application of High Flow nasal cannula in intravenous deep sedation cases in the
      OR will benefit in the reduction of airway manipulation and side effects from general
      anesthesia.

      This study aims to find out the optimal nasal cannula flow rate for maintenance of safe IV
      deep sedation in ophthalmic patients and to assess surgeon and patient satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal flow rate</measure>
    <time_frame>During the surgery</time_frame>
    <description>The optimal flow rate stabilized for the patient which is determined by the oxygen saturation (%)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>High-flow Nasal Cannula</condition>
  <condition>Intravenous Sedation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>High flow rate of 5 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 15 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 30 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 60 L/min and FiO2 of 40%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (15 L/m)</intervention_name>
    <description>nasal cannula at a flow rate of 15 l/min and FiO2 of 40%</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (30 L/m)</intervention_name>
    <description>nasal cannula at a flow rate of 30l/min and FiO2 of 40%</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (60 L/m)</intervention_name>
    <description>nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient able to give consent.

          2. Patient undergoing deep sedation.

          3. Patient undergoing ophthalmic surgeries with no restrictions on the duration of the
             surgery.

          4. Age &gt; 18 years

          5. Patients with BMI &lt; 40 kg/m2

        Exclusion Criteria:

          1. patient unable to give consent

          2. Patient refusal to participate

          3. Patients undergoing general anesthesia

          4. age less than 18 years old

          5. Patients with severe heart failure (EF&lt;30%)

          6. Morbidly obese Patients with BMI &gt; 40 kg/m2

          7. Patients with sleep apnea

          8. Claustrophobia

          9. Risk of aspiration due to severe reflux

         10. Facial injury, facial malformation

         11. Nasal defects/obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Christine El-Yahchouchi</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine El-yahchouchi, M.D.</last_name>
      <phone>00-961-350-000</phone>
      <phone_ext>6380</phone_ext>
      <email>ce18@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Christine El Yahchouchi</investigator_full_name>
    <investigator_title>Instructor of Clinical Specialty</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

